What are the side effects of Dacomitinib?

In clinical studies of patients receiving dacomitinib (Dacomitinib) for the treatment of non-small cell lung cancer, the most common adverse reactions (>20%) were diarrhea, rash, paronychia, oral Inflammation, decreased appetite, dry skin, weight loss, alopecia, cough and pruritus, laboratory abnormalities include anemia, lymphopenia, hypoalbuminemia, elevated ALT, hyperglycemia, elevated AST, hypocalcemia, hypokalemia, hyponatremia, elevated creatinine, increased alkaline phosphatase, hypomagnesemia, and hyperbilirubinemia.

Serious adverse reactions occurred in 27% of patients treated with dacomitinib, and the most common (≥1%) serious adverse reactions were diarrhea and interstitial lung disease; 57% of treated patients experienced dose interruption, the most common (>5%) adverse reactions It should be rash, paronychia, and diarrhea; 66% of treated patients experienced dose reduction, and the most common adverse reactions were rash, paronychia, and diarrhea; 18% of patients experienced adverse reactions that led to the permanent discontinuation of dacomitinib, namely rash, interstitial lung disease, stomatitis, and diarrhea.

The original drug of dacomitinib has been launched in China and has entered the scope of Class B medical insurance. The price of the common specification 15mg*30 tablets per box may be more than 1,000 yuan; the European version of dacomitiniboriginal drug sold overseas, the specification 45mg*30 tablets may be more than 20,000 yuan per box (the price may fluctuate due to exchange rates). Currently, there are cheaper generic drugs of dacomitinib sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 45mg*30 tablets produced by a Lao pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to exchange rate effects).